‘Best yet’ malaria vaccine developers eye 2023 . rollout

[OUAGADOUGOU] Researchers say they plan to release a new file malaria Next year’s vaccine after testing children In West Africa, it has been found to be up to 80 percent effective.

More than 100 malaria vaccines have undergone human trials in recent decades, but none have previously met the WHO’s 75 percent efficacy target.

Scientists have warned This progress in mosquito control has stalled illnesswhich caused more than 640,000 deaths in 2020, most of them children in sub-Saharan Africa.

“This is another precedent in the history of malaria vaccine research.”

Halidou Tinto, Regional Director, Health Sciences Research Institute, Burkina Faso

The booster vaccine for the candidate malaria vaccine, called R21, showed 80 percent efficacy on children who received the highest dose one year after the first dose, researchers from the University of Oxford and the Research Institute of Health Sciences (IRSS) in Nanoru, Burkina Faso, said. Three-dose course.

A 78 percent efficacy was maintained for two years after the booster was given during the trial of 450 children aged 5 to 17 months at the NanoRu Clinical Research Unit. The researchers say there were no serious side effects.

said Halidou Tinto, IRSS regional director, a professor of parasitology and principal investigator on the trial. SciDev.Net . NetworkThis is another first in the history of malaria vaccine research.

“This means that we can maintain efficacy of more than 75 percent in the long term if we give a booster dose and this would enable children who live in malaria-endemic areas such as Burkina to be most at risk.”

The vaccine — which Tinto describes as an improved version of RTS vaccine, S Which is being rolled out in a number of African countries – has already shown 77 percent efficacy in the first year in a previous trial in 2021.

The phase II trial was extended for another two years to assess whether additional booster doses would be needed to maintain this high efficacy over time.

Tinto says he is “optimistic” that the latest results can be replicated in the ongoing Phase III trial involving 4,800 children in Burkina Faso, Mali, Kenya and Tanzania. Expected results later this year.

2023 Subtraction

The R21 vaccine, which was developed at Oxford University’s Jenner Institute, is licensed for production by the Serum Institute of India (SII).

“We are already planning, in cooperation with our partners … to carry out a programmatic roll-out of R21 from 2023 to at least 250,000 children in Burkina Faso, in order to accelerate the agenda of widespread dissemination of this vaccine in Burkina Faso,” said Tinto.

He said SII was committed to producing at least 100-200 million doses of the R21 vaccine annually pending a WHO recommendation for its publication. “This will complement the only vaccine currently recommended by the World Health Organization (RTS, S) whose current production capacity cannot meet global demand,” Tinto added.

RTS,S, the world’s first malaria vaccine, recommended by the World Health Organization in October 2021, for use in at-risk children in sub-Saharan Africa and other regions with moderate to high transmission of malaria-induced disease. Plasmodium falciparum parasite.

However, scientists stressed the need for more vaccine development and research investment.

Director of the Jenner Institute, Adrian Hill, co-author of the R21 study published in Lancet Infectious DiseasesThis, he said, was the “best data to date” of any malaria vaccine.

“We are pleased to find that a standard four-dose immunization regimen can now, for the first time, reach the two-year level of high efficacy that has been an ambitious target for malaria vaccines for many years,” he said.

He said the vaccine would give “lasting protection” to the most needy group: young African children. But he stressed that the vaccine’s 77 percent accuracy depends on other control measures such as insecticides and bed nets, which should continue to be used.

James Tibandrana, who will take over as CEO of the nonprofit Malaria Federation in October, called the results “fantastic.”

Tibandrana, who was not involved in the R21 trials, said the rapid development and roll-out COVID-19 Vaccines showed that the time frame for vaccine development and distribution could have been shortened while still mitigating risks.

“I hope these findings will stimulate increased and continued investments in research and development for malaria vaccines, and equitable access to them, as they prevent malaria and save lives,” he said.

This piece was produced by the SciDev.Net Global Office.